| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1468-2982.2000.00004.X |
| P698 | PubMed publication ID | 10817444 |
| P50 | author | Peer Carsten Tfelt-Hansen | Q78649226 |
| Jes Olesen | Q29643374 | ||
| P2093 | author name string | H-C Diener | |
| V Pfaffenrath | |||
| R Zupping | |||
| G Geraud | |||
| R Sweet | |||
| P2860 | cites work | Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group | Q39452008 |
| Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache | Q39485720 | ||
| Methodology of clinical trials of sumatriptan in migraine and cluster headache | Q39513382 | ||
| 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists | Q41384969 | ||
| Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine | Q41661654 | ||
| Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). | Q48547455 | ||
| Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. | Q48715691 | ||
| Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? | Q48896233 | ||
| Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study | Q57024812 | ||
| Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors | Q34608627 | ||
| Prevalence and sex-ratio of the subtypes of migraine. | Q34721342 | ||
| Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption | Q36329540 | ||
| Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. | Q36723711 | ||
| Verbal scales in the acute treatment of migraine: semantic categories and clinical relevance. | Q38457483 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | migraine | Q133823 |
| P304 | page(s) | 30-38 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Cephalalgia | Q5063251 |
| P1476 | title | Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design | |
| P478 | volume | 20 |
| Q34524980 | A quantification of the placebo response in migraine prophylaxis |
| Q36380205 | AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks |
| Q28192002 | Advances in pharmacological treatment of migraine |
| Q57847675 | Application of the BRAT Framework to Case Studies: Observations and Insights |
| Q34558594 | Assessing the efficacy of drugs for the acute treatment of migraine: issues in clinical trial design |
| Q37008907 | Clinical pharmacology of the serotonin receptor agonist, zolmitriptan |
| Q37177502 | Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials |
| Q42673932 | Distribution of intranasal C-zolmitriptan assessed by positron emission tomography |
| Q36260908 | Does sumatriptan cross the blood-brain barrier in animals and man? |
| Q34155949 | Drug comparisons: why are they so difficult? |
| Q40385073 | Economic and patient-reported outcomes of oral triptans in the treatment of migraine |
| Q30646143 | Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine |
| Q35209630 | Ethical aspects of placebo in migraine research |
| Q40219739 | Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine. |
| Q30692301 | How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials |
| Q34691359 | Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability |
| Q30831647 | Network meta-analysis of migraine disorder treatment by NSAIDs and triptans |
| Q35822040 | OnabotulinumtoxinA for chronic migraine: a critical appraisal. |
| Q36511332 | Optimizing migraine therapy: evidence-based and patient-centered care |
| Q24203742 | Oral sumatriptan for acute migraine |
| Q24248078 | Oral sumatriptan for acute migraine |
| Q39356656 | Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study |
| Q39381589 | Patient preference in clinical trials for headache medication: the patient's view |
| Q34235325 | Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review |
| Q36013751 | Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls |
| Q46377572 | Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine |
| Q35194407 | Safety profile of the triptans |
| Q24203707 | Sumatriptan (oral route of administration) for acute migraine attacks in adults |
| Q38066258 | Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine |
| Q39384899 | The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. |
| Q34813721 | The importance of placebo in headache research |
| Q35107741 | The triptan formulations : how to match patients and products |
| Q34205890 | The triptan formulations: a critical evaluation |
| Q79385330 | Treatment of headache pain with botulinum neurotoxins |
| Q35696691 | Triptans and chest symptoms: the role of pulmonary vasoconstriction |
| Q35610934 | Triptans for treatment of acute pediatric migraine: a systematic literature review |
| Q34127399 | Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy |
| Q46955158 | Triptans in the treatment of migraine: drug selection by means of the SOJA method |
| Q34548435 | Triptans: do they differ? |
| Q88754393 | Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial |
| Q44171180 | Which triptan is best? Rating of triptans in migraine treatment |
| Q36107241 | Zolmitriptan (Zomig). |
| Q24194592 | Zolmitriptan for acute migraine attacks in adults |
Search more.